Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
15 pending office actions • 12 clients • 15 examiners • 10 art units • 0 of 15 (0%) have an AI response strategy ready
Torrey Pines Law Group, PC specializes in the Biotechnology & Pharmaceuticals technology area, having managed 700 career applications. The firm maintains a resolved allowance rate of 85.6 percent, demonstrating a high level of success in securing patents within this complex field. This success rate is based on a volume of 700 career applications, providing a reliable indicator of historical performance.
The firm's current workload includes 11 pending office actions, showing active engagement with the patent office. Their prosecution process averages 3.03 office actions per allowance. This metric suggests a balanced approach to negotiation, achieving an 85.6 percent resolved allowance rate through persistent effort. For practitioners in the Biotechnology & Pharmaceuticals sector, the 3.03 average office actions per allowance offers a realistic expectation for the duration of the prosecution cycle when working with this firm. This data provides a clear picture of the firm's established presence in life sciences.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (20%) |
| §103 only | 3 (20%) |
| §112 only | 1 (7%) |
| Double-patenting + other | 4 (27%) |
| Multi-statute (no §101) | 3 (20%) |
| No statute on record | 1 (7%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZEMAN, ROBERT A | 1 | 54.3% | +27.7% |
| COOPER, JONATHAN EPHRAIM | 1 | 46.1% | +31.3% |
| OLSON, LARS A | 1 | 81.9% | +14.0% |
| CHANG, AUDREY Y | 1 | 46.5% | +20.4% |
| BROCKINGTON III, WILLIAM S | 1 | 42.2% | +54.9% |
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
| D' AMBROSIO, THEA | 1 | 55.3% | +56.1% |
| PELLEGRINO, BRIAN E | 1 | 55.2% | +35.6% |
| TAKENAKA, RISA | 1 | 27.3% | +100.0% |
| MERRIAM, AARON ROGERS | 1 | 31.6% | +63.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18336987 | SYSTEM AND METHOD FOR CORRELATING OXIMETER MEASUREMENTS WITH BLOOD PRESSURE | MERRIAM, AARON ROGERS | 71d |
| 18872768 | STAPHYLOCOCCUS AUREUS VACCINE | ZEMAN, ROBERT A | — |
| 18964380 | SYSTEM AND METHOD FOR USING BLOOD FLOW MEASUREMENTS TO DIAGNOSE AND TREAT HEALTH FUNCTIONS | COOPER, JONATHAN EPHRAIM | — |
| 18843668 | CLOUD-BASED REMOTE VIDEO PRODUCTION PLATFORM | BROCKINGTON III, WILLIAM S | — |
| 18281273 | SYSTEMS AND METHODS FOR DEPLOYING STENTS | PELLEGRINO, BRIAN E | — |
| 18339962 | ENGINEERED CYCLIC PEPTIDES FOR ENHANCING VIRAL PRODUCTION | TAKENAKA, RISA | — |
| 17743407 | PROTEINASE K FREE NUCLEIC ACID EXTRACTION BUFFER SYSTEM | WANG, RUIXUE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18336987 | SYSTEM AND METHOD FOR CORRELATING OXIMETER MEASUREMENTS WITH BLOOD PRESSURE | MERRIAM, AARON ROGERS | 71d |
| 18872768 | STAPHYLOCOCCUS AUREUS VACCINE | ZEMAN, ROBERT A | — |
| 18964380 | SYSTEM AND METHOD FOR USING BLOOD FLOW MEASUREMENTS TO DIAGNOSE AND TREAT HEALTH FUNCTIONS | COOPER, JONATHAN EPHRAIM | — |
| 18929467 | SYSTEM AND METHOD FOR WAVE PREDICTION | OLSON, LARS A | — |
| 18887926 | LABEL-FREE IDENTIFICATION OF TUMOR TISSUES BY COHERENT NONLINEAR VIBRATIONAL MODE IMAGING | CHANG, AUDREY Y | — |
| 18843668 | CLOUD-BASED REMOTE VIDEO PRODUCTION PLATFORM | BROCKINGTON III, WILLIAM S | — |
| 18800564 | Oral Formulation of Clonidine and Midazolam for Sedation in Dental Procedures | COLEMAN, BRENDA LIBBY | — |
| 18509195 | MODIFIED B-TYPE NATRIURETIC PEPTIDE | D' AMBROSIO, THEA | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 2872 | 1 |
| 3623 | 1 |
| 3799 | 1 |
| 1632 | 1 |
| 3791 | 1 |
| 1727 | 1 |
| 3785 | 1 |
| 1672 | 1 |
| 1636 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18872768 | STAPHYLOCOCCUS AUREUS VACCINE | The Regents of the University of California | ZEMAN, ROBERT A | §101§102§112 | Non-Final OA | — | Pending | Dec 06, 2024 | |
| 18964380 | SYSTEM AND METHOD FOR USING BLOOD FLOW MEASUREMENTS TO DIAGNOSE AND TREAT HEALTH FUNCTIONS | Guy P. Curtis | COOPER, JONATHAN EPHRAIM | §101§112 | Non-Final OA | — | Pending | Nov 30, 2024 | |
| 18929467 | SYSTEM AND METHOD FOR WAVE PREDICTION | Re Vision Consulting, LLC | OLSON, LARS A | Other | Non-Final OA | — | Pending | Oct 28, 2024 | |
| 18887926 | LABEL-FREE IDENTIFICATION OF TUMOR TISSUES BY COHERENT NONLINEAR VIBRATIONAL MODE IMAGING | The Regents of the University of California | CHANG, AUDREY Y | 2872 | §103 | Final Rejection | — | Pending | Sep 17, 2024 |
| 18843668 | CLOUD-BASED REMOTE VIDEO PRODUCTION PLATFORM | Advanced Image Robotics, Inc. | BROCKINGTON III, WILLIAM S | 3623 | §101§103§112 | Final Rejection | — | Pending | Sep 03, 2024 |
| 18800564 | Oral Formulation of Clonidine and Midazolam for Sedation in Dental Procedures | Transdermal Sedation Solutions, LLC | COLEMAN, BRENDA LIBBY | §102§112DP | Non-Final OA | — | Pending | Aug 12, 2024 | |
| 18509195 | MODIFIED B-TYPE NATRIURETIC PEPTIDE | Antlia Bioscience, Inc. | D' AMBROSIO, THEA | 1654 | §103§112DP | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18281273 | SYSTEMS AND METHODS FOR DEPLOYING STENTS | Skw Cardiovascular Technologies, Inc. | PELLEGRINO, BRIAN E | 3799 | §103§112 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18339962 | ENGINEERED CYCLIC PEPTIDES FOR ENHANCING VIRAL PRODUCTION | Synvivia, Inc. | TAKENAKA, RISA | 1632 | §103§112DPOther | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18336987 | SYSTEM AND METHOD FOR CORRELATING OXIMETER MEASUREMENTS WITH BLOOD PRESSURE | Guy P. Curtis And Frances L. Curtis Trust | MERRIAM, AARON ROGERS | 3791 | §103§112 | Final Rejection | 71d | Pending | Jun 17, 2023 |
| 18022971 | SILICON COMPOSITE ANODE MATERIALS FOR Li-ION BATTERIES | The Regents of the University of California | WEI, ZHONGQING | 1727 | §103 | Final Rejection | — | Pending | Feb 23, 2023 |
| 17916817 | INHALER SYSTEMS | Purcell Global Ltd. | BALLER, KELSEY E | 3785 | §103 | Non-Final OA | — | Pending | Oct 04, 2022 |
| 17743407 | PROTEINASE K FREE NUCLEIC ACID EXTRACTION BUFFER SYSTEM | Reditus Laboratories, LLC | WANG, RUIXUE | 1672 | §103§112 | Final Rejection | — | Pending | May 12, 2022 |
| 17430664 | CO-FORMULATIONS OF AMYLIN ANALOGUES WITH INSULIN ANALOGUES FOR TREATMENT OF DIABETES | The Board Of Trustees Of The Leland Stanford Junior University | SABILA, MERCY HELLEN | 1654 | §112DP | Non-Final OA | — | Pending | Aug 12, 2021 |
| 17324383 | METHODS AND SYSTEMS FOR DETECTION OF KIDNEY DISEASE OR DISORDER BY GENE EXPRESSION ANALYSIS | The Regents of the University of California | REGA, KYLE THOMAS | 1636 | §112 | Non-Final OA | — | Pending | May 19, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial